Abstract
Psoriasis is a chronic-inflammatory skin disease. In case of moderate and severe psoriasis (approximately 20-30 % of all patients), systemic treatment is necessary. Recent findings regarding the pathomechanism of psoriasis led to the development of targeting molecules, so-called biologics. These biotechnical products are able to selectively block mediators that are relevant for inflammation or to block the interaction between cells, imitating or inhibiting natural proteins.
| Translated title of the contribution | Treatment of psoriasis with biologics |
|---|---|
| Original language | German |
| Journal | Haut |
| Volume | 18 |
| Issue number | 1 |
| Pages (from-to) | 6-9 |
| Number of pages | 4 |
| ISSN | 0938-2216 |
| Publication status | Published - 02.2007 |
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
